ScreenerHero

PPBT Purple Biotech Ltd

NAS · US · Healthcare · Biotechnology · purple-biotech.com
1.460USD-0.68%Mkt Cap: 2.38M $P/E: —

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humaniz…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.38M USD
Enterprise Value-4.43M USD
Revenue (TTM)—
Gross Profit-59.00K USD
Net Income (TTM)-26.39M USD
Revenue/Share—
Last Price1.460 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees10
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.46
PEG—
EV/EBITDA0.56
EV/Revenue—
P/S—
P/B0.12
EPS (TTM)-47.64
EPS (Forward)-1.01
52W Range
1.1602% of range14.10
52W High14.10 USD
52W Low1.160 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-271.63%
ROA-150.16%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.66M USD
CapEx (TTM)3.00K USD
FCF Margin—
FCF Yield-206.44%
Net Debt-5.97M USD
Net Debt/EBITDA0.76
Balance Sheet
Debt/Equity0.03
Current Ratio3.70
Quick Ratio3.42
Book Value/Sh12.00 USD
Cash/Share5.62 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateAug 21, 2020
Splits
Last Split1:10
Split DateMar 2, 2026
Analyst Consensus
Rating—
Target (Mean)17.00 USD
Upside (mean)+1064.4%
Target Range17.00 USD – 17.00 USD
# Analysts1
Ownership
Shares Out.1.63M
Float1.08M
Insiders0.00%
Institutions10.83%
Short Interest
Short Ratio0.0d
Short % Float4.98%
Short % Out.4.98%
Shares Short80.94K
Short (prev mo.)26.16K
Technical
SMA 501.571 (-7.1%)
SMA 2003.564 (-59.0%)
Beta-0.55
S&P 52W Chg15.78%
Avg Vol (30d)2.64M
Avg Vol (10d)27.16K
Technical Indicators
RSI (14)41.2
MACD-0.0413
MACD Signal-0.0299
MACD Hist.-0.0115
BB Upper1.859 USD
BB Middle1.588 USD
BB Lower1.316 USD
BB Width34.17%
ATR (14)0.1551 USD
Vol Ratio (20d)0.11x